Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Surg. Jan 27, 2024; 16(1): 95-102
Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.95
Table 1 Descriptive statistics for patients in the National Surgical Quality Improvement Program hepatectomy targeted dataset diagnosed gallbladder cancer, 2015-2019, n (%)
Characteristic
No neoadjuvant chemotherapy (n = 400)
Neoadjuvant chemotherapy (n = 52)
P value
Sex0.72
Female267 (59.1)36 (8.0)
Male133 (29.4)16 (3.5)
Race0.70
White241 (53.3)35 (7.7)
Black or African American38 (8.4)4 (0.9)
Asian30 (6.6)5 (1.1)
Other2 (0.5)0 (0)
Unknown/Not reported89 (19.7)8 (1.8)
Ethnicity0.19
Not Hispanic293 (64.8)41 (9.1)
Hispanic39 (8.6)7 (1.6)
Unknown/not reported68 (15.0)4 (0.9)
Diabetes 93 (20.6)8 (1.8)0.20
History of smoking 43 (9.5)3 (0.7)0.26
Dyspnea19 (4.2)2 (0.4)1.00
History of chronic obstructive pulmonary disease19(4.2)2 (0.4)1.00
History of congestive heart failure3 (0.7)0 (0.0)1.00
Hypertension requiring medication238 (52.7)24 (5.3)0.07
Steroid use for chronic condition 9 (2.0)2 (0.4)0.37
> 10% loss body weight in last 6 mo19 (4.2)5 (1.1)0.18
Biliary stent (Yes)46 (10.3)6 (1.3)0.97
T (tumor) stage0.91
T0 & T143 (9.5)6 (1.3)
T2140 (31.0)17 (3.8)
T3 & T4136 (30.1)21 (4.7)
Tx & Unknown68 (15.0)7 (1.5)
N/A13 (2.9)1 (0.2)
N (node) stage0.24
N0147 (32.5)14 (3.1)
N1 & N2122 (27.0)23 (5.1)
Nx & unknown115 (25.5)14 (3.1)
N/A16 (3.5)1 (0.2)
M (metastasis) stage0.61
M0/Mx224 (50.0)34 (7.5)
M121 (4.6)3 (0.7)
Unknown95 (21.0)9 (2.0)
N/A60 (13.3)6 (1.3)
Mean (SD)Mean (SD)
Age67.0 (10.6)64.6 (9.1)0.07
Pre-operative serum albumin3.9 (0.6)3.9 (0.5)0.65
Pre-operative total bilirubin0.8 (1.2)0.4 (0.2)< 0.01
Pre-operative BUN15.0 (6.0)16.1 (6.8)0.33
Pre-operative serum creatinine0.9 (0.3)0.9 (0.3)0.45
Pre-operative INR 1.0 (0.1)1.0 (0.1)0.66